eUpdate – Hepatocellular Carcinoma Algorithm
Published: 05 March 2021. Authors: ESMO Guidelines Committee
Note: This eUpdate replaces all previous algorithm eUpdates.
Clinical Practice Guidelines
This eUpdate refers to Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vogel A, Cervantes A, Chau I et al. Ann Oncol 2018; 29 (Suppl 4): iv238–iv255.
Figure 1. HCC treatment options depending on BCLC stage
This eUpdate provides an updated version of Figure 1.
a Non-standard, alternative treatment.
b ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.
c Non-inferiority to sorafenib established; no evaluable benefit.
d Regorafenib is not recommended in TKI-naive patients.
e Ramucirumab is only recommended in patients with an AFP level ≥ 400 ng/ml.
AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; EMA, European Medicines Agency; HCC, hepatocellular carcinoma; LTX, liver transplantation; MCBS, ESMO-Magnitude of Clinical Benefit Scale; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiotherapy; TACE, transarterial chemoembolisation; TKI, tyrosine kinase inhibitor.